Simmunome Inc. is a Canadian computational biology company developing AI-enabled disease modeling technologies to improve the discovery, validation, and clinical translation of therapeutic targets and biomarkers.
Simmunome’s platform integrates multi-omics data—including proteomics, metabolomics, transcriptomics, genomics, and clinical data—using a hybrid mechanistic-AI approach that combines biological pathway knowledge with machine learning. This design enables interpretable, mechanism-aware models that connect molecular measurements to disease phenotypes and clinical outcomes.
The company’s technology has demonstrated strong predictive performance across multiple disease areas, including oncology and immune-mediated conditions, and has been applied to patient stratification, biomarker discovery, and in-silico clinical trial simulation. Simmunome’s models are designed to operate within governed research environments and to support collaborative validation across diverse datasets and institutions.
Through its participation in the Digital Health & Discovery Platform (DHDP), Simmunome aims to contribute advanced computational disease modeling capabilities, support multi-omics data integration and validation, and help establish scalable, reproducible AI approaches that accelerate precision medicine research in Canada.